MedTrace Logo

Dose-Ranging Study of SKF7® for Obesity

NCT05851599 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 142

Last updated 2023-05-09

No results posted yet for this study

Summary

This study has been designed as a randomized, double blinded, multi-centric, placebo controlled and phase II dose-ranging study. One group will receive placebo alone and the other three groups will receive IP twice daily (different dosages) for four months.

Conditions

Interventions

OTHER

SKF7® Labisia pumila standardized extract

Botanical extract of Labisia pumila (Kacip Fatimah)

Sponsors & Collaborators

  • Zach Biotech Depot Sdn Bhd

    collaborator UNKNOWN

  • Medika Natura Sdn Bhd

    lead INDUSTRY

Principal Investigators

  • Shalini Vijayasingham, MBBS, MRCPS · Hospital Melaka, Malaysia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-10-12
Primary Completion
2021-08-08
Completion
2021-08-08

Countries

  • Malaysia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05851599 on ClinicalTrials.gov